Imetelstat Is Effective Treatment for Patients with Intermediate-2 or High-Risk Myelofibrosis Who Have Relapsed on or Are Refractory to Janus Kinase Inhibitor Therapy: Results of a Phase 2 Randomized Study of Two Dose Levels
Year: 2018
Type: conference-abstract
Source: Blood
Authors: John Mascarenhas, Rami S. Komrokji, Michele Cavo, Bruno Martino, Dietger Niederwieser, Andreas Reiter, Bart L Scott, Maria R. Baer, Ronald Hoffman, Olatoyosi Odenike, Jacqueline Bussolari, Eugene Zhu, Fei Huang, Esther Rose, Laurie Sherman, Souria Dougherty, Faye M. Feller, Jean-Jacques Kiladjian
Institutions: Icahn School of Medicine at Mount Sinai, Moffitt Cancer Center, University of Bologna, Azienda ospedaliera "Bianchi-Melacrino-Morelli", University Hospital Leipzig, University Medical Centre Mannheim, Fred Hutch Cancer Center, University of Maryland, Baltimore, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Tisch Cancer Institute, University of Chicago, Janssen Research & Development (United States), Hôpital Saint-Louis, Université Paris Diderot
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2898695740